Validation for Arrabina’s Unique Positioning as a Fiber Ingredient
At COMET, we are keen to provide third-party validation that demonstrates the quality and high tolerability of Arrabina® as a nutritional ingredient. To that end, we have now secured FODMAP Friendly certification, verified by the measurably low FODMAP content in our patented prebiotic fiber.
Why care about FODMAPs?
FODMAPs are a collection of short chain carbohydrates and sugar alcohols found in foods naturally or as food additives. It is an acronym with each letter representing a specific carbohydrate type that can trigger gastrointestinal (GI) discomfort in people sensitive to them, namely the 1 in 7 people afflicted with irritable bowel syndrome (IBS). Symptoms on an irritable bowel include excessive gas, abdominal pain, bloating and distension, nausea and changes in bowel habits (diarrhea and/or constipation). FODMAPs include fructose, fructans, galacto-oligosaccharides (GOS), lactose and polyols (e.g., sorbitol and mannitol).
A diet low in FODMAPs (“a Low FODMAP Diet”) is scientifically proven1,2 and is now used internationally as the most effective dietary therapy for symptoms of an irritable bowel. Sadly, people with irritable bowel irregularity in their digestive health are often counseled to 1) follow a Low FODMAP diet and 2) incorporate fiber supplementation, as part of a dietary solution. However, as many commonly used fibers such as chicory root and inulin are high in FODMAPs, there exists a need for low FODMAP fiber options.
Additionally, consumer awareness of these terms and relationships is high, as current U.S. Google Search shows “irritable bowel syndrome” logging a monthly search volume average of 550K queries.3 Related terms and hashtags also follow suit with high total query volume on TikTok.4,5
61.5M views of “Low FODMAP Diet” + #lowfodmap
5.5M views of “Low FODMAP” + #guthealing
4.6M views of “Low FODMAP Diet” + #prebiotics
6.5M views “irritable bowel syndrome” + #lowfodmap
+>1,000% Quarter-over-Quarter growth of views of “Low FODMAP Diet” + #fiber
Arrabina’s Unique Process and Structure
COMET uses a proprietary upcycling extraction process that uses only steam, water and pressure to source our prebiotic “wheat fiber extract” from left over wheat crop stalks. This process untethers Arrabina®’s unique fiber structure from within the wheat stalk, NOT the grain. The resulting long chain polysaccharide structure makes it better tolerated by the gut than oligosaccharides found in other fiber sources. As such, Arrabina® is a well-tolerated ingredient that’s suitable for Low FODMAP (and gluten free) diets and is less likely to cause gas or digestive upset. In fact, results from a double-blind, randomized clinical trial confirm that consumers can take up to 15 grams per day of Arrabina® with no negative gut or bowel reaction.6
See other Clinical, Content and Sustainability Claims held by Arrabina.
Gaining Consumer Trust
Nutritional ingredients are commonly targeted by skeptics and questioned for their validity. People who are sensitive to specific ingredients need to be especially careful. Therefore, placement of third-party verified, certified logos streamlines their search for products they can consume safely.
Inquire with the COMET team about how to incorporate this FODMAP friendly prebiotic fiber in your formulation and gain trust among your consumer base.
- Shepherd SJ, et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome- randomised placebo-controlled evidence Clin. Gastroenterol. Hepatol. 2008;6(7):765-771. http://www.sciencedirect.com/science/article/pii/S1542356508001511.
- Halmos, EP, et al. A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology 2014;146(1)67-75.
- Spate: US Search: Dec 2023 to Nov 2024.
- Spate: Total all time views. TikTok US – Week of Dec 29, 2024.
- Spate: TikTok. US – from Oct 6, 2024 to Dec 29, 2024 vs. Jul 14, 2024 to Oct 6, 2024.
- Chen O, et al. The Effect of Arabinoxylan on Gastrointestinal Tolerance in Generally Healthy Adults: A Randomized, Placebo-Controlled, Crossover Study, Volume 5, Issue Supplement_2, June 2021, Page 304.
